Conclusions The frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non–ergot-derived dopamine agonists, as compared with control subjects.
Conclusions The frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non–ergot-derived dopamine agonists, as compared with control subjects.
结论：与对照组相比，服用培高利特或者卡麦角林的患者临床上发生重要瓣膜返流的频率显著增加，但服用非麦角洐生的多巴胺受体激动剂的患者瓣膜返流的发生率却未增加。